HRP20041154A2 - SUBSTITUTED 3-AMINO-THIENO[2,3-b] PYRIDINE-2-CARBO - Google Patents
SUBSTITUTED 3-AMINO-THIENO[2,3-b] PYRIDINE-2-CARBOInfo
- Publication number
- HRP20041154A2 HRP20041154A2 HR20041154A HRP20041154A HRP20041154A2 HR P20041154 A2 HRP20041154 A2 HR P20041154A2 HR 20041154 A HR20041154 A HR 20041154A HR P20041154 A HRP20041154 A HR P20041154A HR P20041154 A2 HRP20041154 A2 HR P20041154A2
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- thieno
- pyridine
- 6alkyl
- piperidin
- Prior art date
Links
- -1 1-piperazinyl Chemical group 0.000 claims description 232
- 150000001875 compounds Chemical class 0.000 claims description 138
- 239000000203 mixture Substances 0.000 claims description 98
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 87
- 238000006243 chemical reaction Methods 0.000 claims description 80
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 63
- 125000000623 heterocyclic group Chemical group 0.000 claims description 59
- 125000004076 pyridyl group Chemical group 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 46
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 40
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 39
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 239000002904 solvent Substances 0.000 claims description 29
- 150000002148 esters Chemical class 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 26
- 125000003386 piperidinyl group Chemical group 0.000 claims description 25
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 25
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 24
- 125000001544 thienyl group Chemical group 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 19
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 18
- 125000002541 furyl group Chemical group 0.000 claims description 17
- 125000004193 piperazinyl group Chemical group 0.000 claims description 17
- 230000002757 inflammatory effect Effects 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 125000002883 imidazolyl group Chemical group 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 125000002757 morpholinyl group Chemical group 0.000 claims description 14
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 14
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 13
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 claims description 12
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 11
- NFKLVUJJLJOREJ-UHFFFAOYSA-N 3-amino-6-(4-hydroxypiperidin-1-yl)thieno[2,3-b]pyridine-2,4-dicarboxylic acid Chemical compound C=1C(C(O)=O)=C2C(N)=C(C(O)=O)SC2=NC=1N1CCC(O)CC1 NFKLVUJJLJOREJ-UHFFFAOYSA-N 0.000 claims description 11
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 10
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 230000001363 autoimmune Effects 0.000 claims description 8
- 125000003725 azepanyl group Chemical group 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 7
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 150000004702 methyl esters Chemical class 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 125000005983 2,5-diazabicyclo[2.2.1]heptan-2-yl group Chemical group 0.000 claims description 4
- MTIAEVDFLNZWBL-UHFFFAOYSA-N 3-amino-6-(4-amino-4-cyanopiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(N)(C#N)CC1 MTIAEVDFLNZWBL-UHFFFAOYSA-N 0.000 claims description 4
- BZNUHRDIJQWTTQ-UHFFFAOYSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-(4-nitrophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1CC(N)CCN1C1=CC(C=2C=CC(=CC=2)[N+]([O-])=O)=C(C(N)=C(S2)C(N)=O)C2=N1 BZNUHRDIJQWTTQ-UHFFFAOYSA-N 0.000 claims description 4
- JLBBNBJDNWXYBL-VOTSOKGWSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-[(e)-2-phenylethenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1CC(N)CCN1C1=CC(\C=C\C=2C=CC=CC=2)=C(C(N)=C(S2)C(N)=O)C2=N1 JLBBNBJDNWXYBL-VOTSOKGWSA-N 0.000 claims description 4
- OYWOGJOEDCLNEU-UHFFFAOYSA-N 3-amino-6-(4-oxopiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(=O)CC1 OYWOGJOEDCLNEU-UHFFFAOYSA-N 0.000 claims description 4
- DMJAFCNEDMCMCG-NSHDSACASA-N 3-amino-6-[4-[[(2s)-2-hydroxypropyl]amino]piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(NC[C@H](C)O)CC1 DMJAFCNEDMCMCG-NSHDSACASA-N 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 125000005961 oxazepanyl group Chemical group 0.000 claims description 4
- 125000005505 thiomorpholino group Chemical group 0.000 claims description 4
- KHBYHZRMMMNCRG-UHFFFAOYSA-N 3-amino-4-ethoxy-6-(4-hydroxypiperidin-1-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(OCC)=CC=1N1CCC(O)CC1 KHBYHZRMMMNCRG-UHFFFAOYSA-N 0.000 claims description 3
- BVVKINYXDIJKIT-UHFFFAOYSA-N 3-amino-6-(4-amino-4-methylpiperidin-1-yl)-4-ethoxythieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(OCC)=CC=1N1CCC(C)(N)CC1 BVVKINYXDIJKIT-UHFFFAOYSA-N 0.000 claims description 3
- NEEKCMNGBAHAMC-UHFFFAOYSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-ethoxythieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(OCC)=CC=1N1CCC(N)CC1 NEEKCMNGBAHAMC-UHFFFAOYSA-N 0.000 claims description 3
- LYXUMHUYBOQJLB-UHFFFAOYSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-methylsulfanylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(SC)=CC=1N1CCC(N)CC1 LYXUMHUYBOQJLB-UHFFFAOYSA-N 0.000 claims description 3
- IADACRYWVHWRLA-UHFFFAOYSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-propan-2-yloxythieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(OC(C)C)=CC=1N1CCC(N)CC1 IADACRYWVHWRLA-UHFFFAOYSA-N 0.000 claims description 3
- GGXPEWPWJNSCPI-UHFFFAOYSA-N 3-amino-6-(4-hydroxypiperidin-1-yl)-4-(3-hydroxypropyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C(CCCO)=C2C(N)=C(C(=O)N)SC2=NC=1N1CCC(O)CC1 GGXPEWPWJNSCPI-UHFFFAOYSA-N 0.000 claims description 3
- NSUOUCFIOXVTFA-UHFFFAOYSA-N 3-amino-6-piperazin-1-yl-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C(C(F)(F)F)=C2C(N)=C(C(=O)N)SC2=NC=1N1CCNCC1 NSUOUCFIOXVTFA-UHFFFAOYSA-N 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- VXIVSQZSERGHQP-HQMMCQRPSA-N 2-chloroacetamide Chemical group N[14C](=O)CCl VXIVSQZSERGHQP-HQMMCQRPSA-N 0.000 claims description 2
- ALEHIGVCNCPFJF-UHFFFAOYSA-N 3-amino-4-(4-cyano-3-fluorophenyl)-6-(4-hydroxypiperidin-1-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC(N2CCC(O)CC2)=CC=1C1=CC=C(C#N)C(F)=C1 ALEHIGVCNCPFJF-UHFFFAOYSA-N 0.000 claims description 2
- NYRHABRBHITKBD-UHFFFAOYSA-N 3-amino-6-(1h-indol-3-ylmethylamino)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CC=C2C(CNC=3C=C(C=4C(N)=C(C(N)=O)SC=4N=3)CCC)=CNC2=C1 NYRHABRBHITKBD-UHFFFAOYSA-N 0.000 claims description 2
- RWSSJVJKPTXJQL-UHFFFAOYSA-N 3-amino-6-(4-amino-3,3-dimethylcyclohexyl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1C1CCC(N)C(C)(C)C1 RWSSJVJKPTXJQL-UHFFFAOYSA-N 0.000 claims description 2
- GMYKFOPFZNINQR-UHFFFAOYSA-N 3-amino-6-(4-amino-3-hydroxypiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(N)C(O)C1 GMYKFOPFZNINQR-UHFFFAOYSA-N 0.000 claims description 2
- KDDWRPRQCHBICJ-UHFFFAOYSA-N 3-amino-6-(4-aminoazepan-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCCC(N)CC1 KDDWRPRQCHBICJ-UHFFFAOYSA-N 0.000 claims description 2
- DDXLMQIWDFWTFE-UHFFFAOYSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-(2,4-difluorophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1CC(N)CCN1C1=CC(C=2C(=CC(F)=CC=2)F)=C(C(N)=C(S2)C(N)=O)C2=N1 DDXLMQIWDFWTFE-UHFFFAOYSA-N 0.000 claims description 2
- LKBQVRWZCUFPRC-UHFFFAOYSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-(2,5-difluorophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1CC(N)CCN1C1=CC(C=2C(=CC=C(F)C=2)F)=C(C(N)=C(S2)C(N)=O)C2=N1 LKBQVRWZCUFPRC-UHFFFAOYSA-N 0.000 claims description 2
- FPBFUNNLBPPXDL-UHFFFAOYSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-(4-cyano-3-fluorophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1CC(N)CCN1C1=CC(C=2C=C(F)C(C#N)=CC=2)=C(C(N)=C(S2)C(N)=O)C2=N1 FPBFUNNLBPPXDL-UHFFFAOYSA-N 0.000 claims description 2
- PMEHDKFOFXOLRY-VOTSOKGWSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-[(e)-2-(4-methylphenyl)ethenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CC(C)=CC=C1\C=C\C1=CC(N2CCC(N)CC2)=NC2=C1C(N)=C(C(N)=O)S2 PMEHDKFOFXOLRY-VOTSOKGWSA-N 0.000 claims description 2
- SFRFRKNOPPYTOS-UHFFFAOYSA-N 3-amino-6-(4-hydroxypiperidin-1-yl)-4-(4-methylsulfonylphenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(N2CCC(O)CC2)=NC2=C1C(N)=C(C(N)=O)S2 SFRFRKNOPPYTOS-UHFFFAOYSA-N 0.000 claims description 2
- FGNMZEZEQQMLDQ-UHFFFAOYSA-N 3-amino-6-[2-(aminomethyl)piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCCCC1CN FGNMZEZEQQMLDQ-UHFFFAOYSA-N 0.000 claims description 2
- ROKNIKLGTCUQSG-UHFFFAOYSA-N 3-amino-6-[4-(2-hydroxyethylamino)piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(NCCO)CC1 ROKNIKLGTCUQSG-UHFFFAOYSA-N 0.000 claims description 2
- UAAXDGAQLNVGJU-UHFFFAOYSA-N 3-amino-6-[4-(anilinocarbamoyl)piperazin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N(CC1)CCN1C(=O)NNC1=CC=CC=C1 UAAXDGAQLNVGJU-UHFFFAOYSA-N 0.000 claims description 2
- IXXUOEYLTTUTOD-UHFFFAOYSA-N 3-amino-6-[4-(carbamoylamino)piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(NC(N)=O)CC1 IXXUOEYLTTUTOD-UHFFFAOYSA-N 0.000 claims description 2
- CREAHTMWKXOTPH-UHFFFAOYSA-N 3-amino-6-[4-(methanesulfonamido)piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(NS(C)(=O)=O)CC1 CREAHTMWKXOTPH-UHFFFAOYSA-N 0.000 claims description 2
- ZAAYLLURXCAEMP-UHFFFAOYSA-N 3-amino-6-[4-[(2-hydroxy-2-phenylethyl)amino]piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N(CC1)CCC1NCC(O)C1=CC=CC=C1 ZAAYLLURXCAEMP-UHFFFAOYSA-N 0.000 claims description 2
- UMLYAHRGHSFGGN-UHFFFAOYSA-N 3-amino-6-piperidin-4-yl-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1C1CCNCC1 UMLYAHRGHSFGGN-UHFFFAOYSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- SZTTUBLYHXHAML-UHFFFAOYSA-N 4-[2-[[1-(3-amino-2-carbamoyl-4-propylthieno[2,3-b]pyridin-6-yl)piperidin-4-yl]amino]-1-hydroxyethyl]benzoic acid Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N(CC1)CCC1NCC(O)C1=CC=C(C(O)=O)C=C1 SZTTUBLYHXHAML-UHFFFAOYSA-N 0.000 claims description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010048768 Dermatosis Diseases 0.000 claims description 2
- 206010018366 Glomerulonephritis acute Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000003807 Graves Disease Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 231100000851 acute glomerulonephritis Toxicity 0.000 claims description 2
- 208000005298 acute pain Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- LBVMBECAHIBYAO-UHFFFAOYSA-N methyl 4-[3-amino-6-(4-aminopiperidin-1-yl)-2-carbamoylthieno[2,3-b]pyridin-4-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=CC(N2CCC(N)CC2)=NC2=C1C(N)=C(C(N)=O)S2 LBVMBECAHIBYAO-UHFFFAOYSA-N 0.000 claims description 2
- 208000037890 multiple organ injury Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000006187 phenyl benzyl group Chemical group 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- SLZQVXKKOAEGCQ-UHFFFAOYSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-(4-methylsulfonylphenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(N2CCC(N)CC2)=NC2=C1C(N)=C(C(N)=O)S2 SLZQVXKKOAEGCQ-UHFFFAOYSA-N 0.000 claims 1
- LZBBYYQKWSFFRD-UHFFFAOYSA-N 3-amino-6-(4-hydroxycyclohexyl)thieno[2,3-b]pyridine-2,4-dicarboxylic acid Chemical compound C=1C(C(O)=O)=C2C(N)=C(C(O)=O)SC2=NC=1C1CCC(O)CC1 LZBBYYQKWSFFRD-UHFFFAOYSA-N 0.000 claims 1
- BFTZLDBLVOULJR-UHFFFAOYSA-N 3-amino-6-(4-hydroxypiperidin-1-yl)-4-methylsulfanylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(SC)=CC=1N1CCC(O)CC1 BFTZLDBLVOULJR-UHFFFAOYSA-N 0.000 claims 1
- HOBJMKPFDIKUPK-AXDSSHIGSA-N 3-amino-6-[(3s)-3,4-dihydroxypiperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(O)[C@@H](O)C1 HOBJMKPFDIKUPK-AXDSSHIGSA-N 0.000 claims 1
- ZJOOYMHAYDMUDS-DTIOYNMSSA-N 3-amino-6-[(3s)-3-hydroxy-4-(methanesulfonamido)piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(NS(C)(=O)=O)[C@@H](O)C1 ZJOOYMHAYDMUDS-DTIOYNMSSA-N 0.000 claims 1
- APGBNEUAEYXLJH-UHFFFAOYSA-N 3-amino-6-[4-(2-methylsulfonylhydrazinyl)piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(NNS(C)(=O)=O)CC1 APGBNEUAEYXLJH-UHFFFAOYSA-N 0.000 claims 1
- QMHJGOPVDQIXAL-UHFFFAOYSA-N NC1=C(SC2=NC(=CC(=C21)CCC)N2CCN(CC2)C(C(CCN)N)=O)C(=O)N.NC2=C(SC1=NC(=CC(=C12)CCC)N1CCNCCC1)C(=O)N Chemical compound NC1=C(SC2=NC(=CC(=C21)CCC)N2CCN(CC2)C(C(CCN)N)=O)C(=O)N.NC2=C(SC1=NC(=CC(=C12)CCC)N1CCNCCC1)C(=O)N QMHJGOPVDQIXAL-UHFFFAOYSA-N 0.000 claims 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 198
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 112
- 239000000243 solution Substances 0.000 description 96
- 239000007787 solid Substances 0.000 description 65
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 55
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- 235000019439 ethyl acetate Nutrition 0.000 description 54
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 43
- 239000000047 product Substances 0.000 description 38
- 230000015572 biosynthetic process Effects 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 238000003786 synthesis reaction Methods 0.000 description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 35
- 239000011541 reaction mixture Substances 0.000 description 33
- 239000000543 intermediate Substances 0.000 description 31
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- 101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 description 27
- 239000002244 precipitate Substances 0.000 description 27
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 25
- 239000000741 silica gel Substances 0.000 description 25
- 229910002027 silica gel Inorganic materials 0.000 description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 239000002585 base Substances 0.000 description 20
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 19
- 150000001408 amides Chemical class 0.000 description 19
- 239000000460 chlorine Substances 0.000 description 19
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- 238000003818 flash chromatography Methods 0.000 description 18
- 108010057466 NF-kappa B Proteins 0.000 description 17
- 102000003945 NF-kappa B Human genes 0.000 description 17
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 239000008346 aqueous phase Substances 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- 229910000029 sodium carbonate Inorganic materials 0.000 description 15
- 235000017550 sodium carbonate Nutrition 0.000 description 15
- 239000012298 atmosphere Substances 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 13
- 238000012746 preparative thin layer chromatography Methods 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 229910000104 sodium hydride Inorganic materials 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- BHPYMZQTCPRLNR-UHFFFAOYSA-N 2-cyanoethanethioamide Chemical compound NC(=S)CC#N BHPYMZQTCPRLNR-UHFFFAOYSA-N 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000005909 Kieselgur Substances 0.000 description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 235000019270 ammonium chloride Nutrition 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 9
- 239000007832 Na2SO4 Substances 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 102000000589 Interleukin-1 Human genes 0.000 description 7
- 108010002352 Interleukin-1 Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 6
- IQDMGUORVIRTSU-UHFFFAOYSA-N 3-amino-6-methylthieno[2,3-b]pyridine-2,4-dicarboxylic acid Chemical compound CC1=CC(C(O)=O)=C2C(N)=C(C(O)=O)SC2=N1 IQDMGUORVIRTSU-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- PSCVYEBXCLQANK-UHFFFAOYSA-N 2-bromo-4-oxo-1h-pyridine-3-carbonitrile Chemical compound BrC=1NC=CC(=O)C=1C#N PSCVYEBXCLQANK-UHFFFAOYSA-N 0.000 description 4
- GYXHHICIFZSKKZ-UHFFFAOYSA-N 2-sulfanylacetamide Chemical compound NC(=O)CS GYXHHICIFZSKKZ-UHFFFAOYSA-N 0.000 description 4
- YMUVNLHJBBMIFJ-UHFFFAOYSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(N)CC1 YMUVNLHJBBMIFJ-UHFFFAOYSA-N 0.000 description 4
- QXSAKPUBHTZHKW-UHFFFAOYSA-N 4-hydroxybenzamide Chemical compound NC(=O)C1=CC=C(O)C=C1 QXSAKPUBHTZHKW-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 4
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000011813 knockout mouse model Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012038 nucleophile Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- SDTORDSXCYSNTD-UHFFFAOYSA-N 1-methoxy-4-[(4-methoxyphenyl)methoxymethyl]benzene Chemical compound C1=CC(OC)=CC=C1COCC1=CC=C(OC)C=C1 SDTORDSXCYSNTD-UHFFFAOYSA-N 0.000 description 3
- MNHPQFWACBMBQT-UHFFFAOYSA-N 3-amino-6-piperazin-1-yl-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCNCC1 MNHPQFWACBMBQT-UHFFFAOYSA-N 0.000 description 3
- 102000006311 Cyclin D1 Human genes 0.000 description 3
- 108010058546 Cyclin D1 Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 150000001263 acyl chlorides Chemical class 0.000 description 3
- 125000005018 aryl alkenyl group Chemical group 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- GZCMARRHFBXBOA-UHFFFAOYSA-N ethyl 3-amino-2-carbamoyl-6-methylthieno[2,3-b]pyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC(C)=NC2=C1C(N)=C(C(N)=O)S2 GZCMARRHFBXBOA-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 229940125670 thienopyridine Drugs 0.000 description 3
- 239000002175 thienopyridine Substances 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
- DLQYXUGCCKQSRJ-UHFFFAOYSA-N tris(furan-2-yl)phosphane Chemical compound C1=COC(P(C=2OC=CC=2)C=2OC=CC=2)=C1 DLQYXUGCCKQSRJ-UHFFFAOYSA-N 0.000 description 3
- POYHRXUCNTYVBV-UHFFFAOYSA-N 1,1,5,5-tetrachloropenta-1,4-dien-3-one Chemical compound ClC(Cl)=CC(=O)C=C(Cl)Cl POYHRXUCNTYVBV-UHFFFAOYSA-N 0.000 description 2
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 2
- OUKQTRFCDKSEPL-UHFFFAOYSA-N 1-Methyl-2-pyrrolecarboxaldehyde Chemical compound CN1C=CC=C1C=O OUKQTRFCDKSEPL-UHFFFAOYSA-N 0.000 description 2
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 2
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 2
- LSJALJLZXACYJQ-UHFFFAOYSA-N 2-[3-cyano-4-propyl-6-(trifluoromethylsulfonyl)pyridin-2-yl]sulfanylacetamide Chemical compound CCCC1=CC(S(=O)(=O)C(F)(F)F)=NC(SCC(N)=O)=C1C#N LSJALJLZXACYJQ-UHFFFAOYSA-N 0.000 description 2
- ZFXCZHOONZKJKL-UHFFFAOYSA-N 3-amino-2-carbamoyl-6-methylthieno[2,3-b]pyridine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=C2C(N)=C(C(N)=O)SC2=N1 ZFXCZHOONZKJKL-UHFFFAOYSA-N 0.000 description 2
- NGRLVWVUVXKGKY-UHFFFAOYSA-N 3-amino-4-(4-hydroxy-4-phenylpiperidin-1-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1N(CC1)CCC1(O)C1=CC=CC=C1 NGRLVWVUVXKGKY-UHFFFAOYSA-N 0.000 description 2
- NQSCWUIEJRBEFH-UHFFFAOYSA-N 3-amino-4-(hydroxymethyl)-6-methylthieno[2,3-b]pyridine-2-carboxamide Chemical compound CC1=CC(CO)=C2C(N)=C(C(N)=O)SC2=N1 NQSCWUIEJRBEFH-UHFFFAOYSA-N 0.000 description 2
- VOHBMGVYZZGBBJ-UHFFFAOYSA-N 3-amino-4-[(4-methoxyphenyl)methoxy]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1=CC(OC)=CC=C1COC1=CC=NC2=C1C(N)=C(C(N)=O)S2 VOHBMGVYZZGBBJ-UHFFFAOYSA-N 0.000 description 2
- BHVJDFNMLVXHDH-GORDUTHDSA-N 3-amino-4-[(e)-2-(4-chlorophenyl)ethenyl]-6-methylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(N)=O)SC2=NC(C)=CC=1\C=C\C1=CC=C(Cl)C=C1 BHVJDFNMLVXHDH-GORDUTHDSA-N 0.000 description 2
- QLLVZGCESLMUHF-UHFFFAOYSA-N 3-amino-4-formyl-6-methylthieno[2,3-b]pyridine-2-carboxamide Chemical compound CC1=CC(C=O)=C2C(N)=C(C(N)=O)SC2=N1 QLLVZGCESLMUHF-UHFFFAOYSA-N 0.000 description 2
- VXWNIKGBHDEIQO-UHFFFAOYSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1CC(N)CCN1C1=CC(C(F)(F)F)=C(C(N)=C(S2)C(N)=O)C2=N1 VXWNIKGBHDEIQO-UHFFFAOYSA-N 0.000 description 2
- QRXNBBOOEBZCMM-UHFFFAOYSA-N 3-amino-6-(4-hydroxypiperidin-1-yl)-4-methylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C)=CC=1N1CCC(O)CC1 QRXNBBOOEBZCMM-UHFFFAOYSA-N 0.000 description 2
- XSVMYNXJLLCOBL-UHFFFAOYSA-N 3-amino-6-(4-methylpiperazin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCN(C)CC1 XSVMYNXJLLCOBL-UHFFFAOYSA-N 0.000 description 2
- FFUVIZUVYRPFAF-UHFFFAOYSA-N 3-amino-6-[4-(methylamino)piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(NC)CC1 FFUVIZUVYRPFAF-UHFFFAOYSA-N 0.000 description 2
- BLPSKXFKSDZZEA-UHFFFAOYSA-N 3-amino-6-imidazol-1-yl-4-methylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C)=CC=1N1C=CN=C1 BLPSKXFKSDZZEA-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- CFQVMMFFPCCTPS-UHFFFAOYSA-N 3-sulfanyl-1h-pyridin-2-one Chemical compound OC1=NC=CC=C1S CFQVMMFFPCCTPS-UHFFFAOYSA-N 0.000 description 2
- KQGBLRILCYSUFE-UHFFFAOYSA-N 4-(oxiran-2-ylmethoxy)benzamide Chemical compound C1=CC(C(=O)N)=CC=C1OCC1OC1 KQGBLRILCYSUFE-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- PLFIVDUVUDONFL-UHFFFAOYSA-N 4-acetyl-3-amino-6-methylthieno[2,3-b]pyridine-2-carboxamide Chemical compound CC(=O)C1=CC(C)=NC2=C1C(N)=C(C(N)=O)S2 PLFIVDUVUDONFL-UHFFFAOYSA-N 0.000 description 2
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 229910004664 Cerium(III) chloride Inorganic materials 0.000 description 2
- 102000001327 Chemokine CCL5 Human genes 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 102000001284 I-kappa-B kinase Human genes 0.000 description 2
- 108060006678 I-kappa-B kinase Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 108700005075 Regulator Genes Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940124650 anti-cancer therapies Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 150000001543 aryl boronic acids Chemical class 0.000 description 2
- 150000005840 aryl radicals Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- SFJMFSWCBVEHBA-UHFFFAOYSA-M copper(i)-thiophene-2-carboxylate Chemical compound [Cu+].[O-]C(=O)C1=CC=CS1 SFJMFSWCBVEHBA-UHFFFAOYSA-M 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 125000005594 diketone group Chemical group 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- WBMMFDGNOQLZNF-UHFFFAOYSA-N ethyl 3-cyano-6-methyl-2-sulfanylidene-1h-pyridine-4-carboxylate Chemical compound CCOC(=O)C=1C=C(C)NC(=S)C=1C#N WBMMFDGNOQLZNF-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 2
- PJDFBQWQRHRSCF-UHFFFAOYSA-N methyl 4-[(4-methoxyphenyl)methoxy]-3-oxobutanoate Chemical compound COC(=O)CC(=O)COCC1=CC=C(OC)C=C1 PJDFBQWQRHRSCF-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- UCUUFSAXZMGPGH-UHFFFAOYSA-N penta-1,4-dien-3-one Chemical compound C=CC(=O)C=C UCUUFSAXZMGPGH-UHFFFAOYSA-N 0.000 description 2
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 2
- YWVYZMVYXAVAKS-UHFFFAOYSA-N pyridin-1-ium;trifluoromethanesulfonate Chemical compound C1=CC=[NH+]C=C1.[O-]S(=O)(=O)C(F)(F)F YWVYZMVYXAVAKS-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- VTGLVJUYAIALNQ-UHFFFAOYSA-N tert-butyl 4-(3-amino-2-carbamoylthieno[2,3-b]pyridin-4-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=NC2=C1C(N)=C(C(N)=O)S2 VTGLVJUYAIALNQ-UHFFFAOYSA-N 0.000 description 2
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 2
- GCPNPVFWMHBPNS-UHFFFAOYSA-N tert-butyl-dimethyl-piperidin-4-yloxysilane Chemical compound CC(C)(C)[Si](C)(C)OC1CCNCC1 GCPNPVFWMHBPNS-UHFFFAOYSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- SMZMHUCIDGHERP-UHFFFAOYSA-N thieno[2,3-b]pyridine Chemical compound C1=CN=C2SC=CC2=C1 SMZMHUCIDGHERP-UHFFFAOYSA-N 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- ANQICIIKQHSDAP-UHFFFAOYSA-N (3-amino-2-carbamoyl-4-methylsulfanylthieno[2,3-b]pyridin-6-yl) trifluoromethanesulfonate Chemical compound CSC1=CC(OS(=O)(=O)C(F)(F)F)=NC2=C1C(N)=C(C(N)=O)S2 ANQICIIKQHSDAP-UHFFFAOYSA-N 0.000 description 1
- VDUKDQTYMWUSAC-UHFFFAOYSA-N (4-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=C(B(O)O)C=C1 VDUKDQTYMWUSAC-UHFFFAOYSA-N 0.000 description 1
- JWOHBPPVVDQMKB-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C(O)=O)CC1 JWOHBPPVVDQMKB-UHFFFAOYSA-N 0.000 description 1
- YKQMBPQMCWGNDY-UHFFFAOYSA-N 1-benzyl-3,3-dimethylpiperidin-4-one Chemical compound C1CC(=O)C(C)(C)CN1CC1=CC=CC=C1 YKQMBPQMCWGNDY-UHFFFAOYSA-N 0.000 description 1
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KFBXUKHERGLHLG-UHFFFAOYSA-N 2,4-Nonanedione Chemical compound CCCCCC(=O)CC(C)=O KFBXUKHERGLHLG-UHFFFAOYSA-N 0.000 description 1
- SURCGQGDUADKBL-UHFFFAOYSA-N 2-(2-hydroxyethylamino)-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(NCCO)C2=O)=O)=C3C2=CC=CC3=C1 SURCGQGDUADKBL-UHFFFAOYSA-N 0.000 description 1
- RUHJZSZTSCSTCC-UHFFFAOYSA-N 2-(bromomethyl)naphthalene Chemical compound C1=CC=CC2=CC(CBr)=CC=C21 RUHJZSZTSCSTCC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- IVMWWXGZZNZZQF-UHFFFAOYSA-N 2-[[4-[3-[tert-butyl(dimethyl)silyl]oxypropyl]-3-cyano-6-oxo-1h-pyridin-2-yl]sulfanyl]acetamide Chemical compound CC(C)(C)[Si](C)(C)OCCCC1=CC(=O)NC(SCC(N)=O)=C1C#N IVMWWXGZZNZZQF-UHFFFAOYSA-N 0.000 description 1
- GKRKWDWETUTQOT-UHFFFAOYSA-N 2-bromo-2-chloroacetamide Chemical group NC(=O)C(Cl)Br GKRKWDWETUTQOT-UHFFFAOYSA-N 0.000 description 1
- GAVMYVUSFLSUET-UHFFFAOYSA-N 2-bromo-4-[(4-methoxyphenyl)methoxy]pyridine-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1COC1=CC=NC(Br)=C1C#N GAVMYVUSFLSUET-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- MOKUXMQJIYHZCA-UHFFFAOYSA-N 2-chloro-4-methoxypyridine-3-carbonitrile Chemical compound COC1=CC=NC(Cl)=C1C#N MOKUXMQJIYHZCA-UHFFFAOYSA-N 0.000 description 1
- VKEKYGNDJZUZTL-UHFFFAOYSA-N 2-sulfanylidene-1h-pyridine-3-carbonitrile Chemical class S=C1NC=CC=C1C#N VKEKYGNDJZUZTL-UHFFFAOYSA-N 0.000 description 1
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 description 1
- DGLSWRYOGXGBLP-UHFFFAOYSA-N 3,3-dimethylpiperidin-4-amine;dihydrochloride Chemical compound Cl.Cl.CC1(C)CNCCC1N DGLSWRYOGXGBLP-UHFFFAOYSA-N 0.000 description 1
- SDMLKCQDZJOSDN-UHFFFAOYSA-N 3-amino-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide Chemical compound CC1=CC(C)=C2C(N)=C(C(N)=O)SC2=N1 SDMLKCQDZJOSDN-UHFFFAOYSA-N 0.000 description 1
- DHDJIMYHPMEMTR-UHFFFAOYSA-N 3-amino-4,6-dimethylthieno[2,3-b]pyridine-2-carboxylic acid Chemical compound CC1=CC(C)=C2C(N)=C(C(O)=O)SC2=N1 DHDJIMYHPMEMTR-UHFFFAOYSA-N 0.000 description 1
- KENRRTMYURCKOP-UHFFFAOYSA-N 3-amino-4,6-diphenylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC(C=2C=CC=CC=2)=CC=1C1=CC=CC=C1 KENRRTMYURCKOP-UHFFFAOYSA-N 0.000 description 1
- MBKHIODVOZGZQM-UHFFFAOYSA-N 3-amino-4-(1-hydroxy-2-phenylethyl)-6-methylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(N)=O)SC2=NC(C)=CC=1C(O)CC1=CC=CC=C1 MBKHIODVOZGZQM-UHFFFAOYSA-N 0.000 description 1
- MHBFVMRVHITNPZ-UHFFFAOYSA-N 3-amino-4-(3-hydroxypiperidin-1-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1N1CCCC(O)C1 MHBFVMRVHITNPZ-UHFFFAOYSA-N 0.000 description 1
- CSRFDBMSYSBWBC-UHFFFAOYSA-N 3-amino-4-(4-benzylpiperazin-1-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1N(CC1)CCN1CC1=CC=CC=C1 CSRFDBMSYSBWBC-UHFFFAOYSA-N 0.000 description 1
- RHIQFMQQVAGWOA-UHFFFAOYSA-N 3-amino-4-(4-benzylpiperidin-1-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1N(CC1)CCC1CC1=CC=CC=C1 RHIQFMQQVAGWOA-UHFFFAOYSA-N 0.000 description 1
- QFQITODAWFGKDR-UHFFFAOYSA-N 3-amino-4-(4-chlorophenyl)-6-methylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(N)=O)SC2=NC(C)=CC=1C1=CC=C(Cl)C=C1 QFQITODAWFGKDR-UHFFFAOYSA-N 0.000 description 1
- QKQZWQMYLIEIEZ-UHFFFAOYSA-N 3-amino-4-(4-hydroxypiperidin-1-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1N1CCC(O)CC1 QKQZWQMYLIEIEZ-UHFFFAOYSA-N 0.000 description 1
- BVDXJSFSJOYDSP-UHFFFAOYSA-N 3-amino-4-(4-methylpiperazin-1-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1CN(C)CCN1C1=CC=NC2=C1C(N)=C(C(N)=O)S2 BVDXJSFSJOYDSP-UHFFFAOYSA-N 0.000 description 1
- DJJBFRCOLNVEMU-UHFFFAOYSA-N 3-amino-4-(4-nitroanilino)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1NC1=CC=C([N+]([O-])=O)C=C1 DJJBFRCOLNVEMU-UHFFFAOYSA-N 0.000 description 1
- NLYZRJUSAMBMBG-UHFFFAOYSA-N 3-amino-4-(4-phenylpiperazin-1-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1N(CC1)CCN1C1=CC=CC=C1 NLYZRJUSAMBMBG-UHFFFAOYSA-N 0.000 description 1
- LUMORRSYOBDDPE-UHFFFAOYSA-N 3-amino-4-(4-phenylpiperidin-1-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1N(CC1)CCC1C1=CC=CC=C1 LUMORRSYOBDDPE-UHFFFAOYSA-N 0.000 description 1
- PZJBHSWCQXXDBK-UHFFFAOYSA-N 3-amino-4-(4-piperidin-1-ylpiperidin-1-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1N(CC1)CCC1N1CCCCC1 PZJBHSWCQXXDBK-UHFFFAOYSA-N 0.000 description 1
- MDZJOSXEQMJVPR-UHFFFAOYSA-N 3-amino-4-(cyclohexylmethoxy)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1OCC1CCCCC1 MDZJOSXEQMJVPR-UHFFFAOYSA-N 0.000 description 1
- FPDRAPAICDDZAT-UHFFFAOYSA-N 3-amino-4-(furan-2-yl)-6-methylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(N)=O)SC2=NC(C)=CC=1C1=CC=CO1 FPDRAPAICDDZAT-UHFFFAOYSA-N 0.000 description 1
- AICQSHREMAWIIX-UHFFFAOYSA-N 3-amino-4-[(2-hydroxy-2-phenylethyl)-methylamino]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=NC=2SC(C(N)=O)=C(N)C=2C=1N(C)CC(O)C1=CC=CC=C1 AICQSHREMAWIIX-UHFFFAOYSA-N 0.000 description 1
- KKHMTGGUJUUYGS-UHFFFAOYSA-N 3-amino-4-[(3-methoxyphenyl)methoxy]thieno[2,3-b]pyridine-2-carboxamide Chemical compound COC1=CC=CC(COC=2C=3C(N)=C(C(N)=O)SC=3N=CC=2)=C1 KKHMTGGUJUUYGS-UHFFFAOYSA-N 0.000 description 1
- BZVQREJPPVBQCO-UHFFFAOYSA-N 3-amino-4-[(4-carbamoylphenoxy)methyl]-6-methylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(N)=O)SC2=NC(C)=CC=1COC1=CC=C(C(N)=O)C=C1 BZVQREJPPVBQCO-UHFFFAOYSA-N 0.000 description 1
- BZVXLVDWNXKHBQ-GORDUTHDSA-N 3-amino-4-[(e)-2-(4-fluorophenyl)ethenyl]-6-methylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(N)=O)SC2=NC(C)=CC=1\C=C\C1=CC=C(F)C=C1 BZVXLVDWNXKHBQ-GORDUTHDSA-N 0.000 description 1
- ASDIESYCZFFZGW-UHFFFAOYSA-N 3-amino-4-[4-(2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C12=CC=CC=C2NC(=O)N1C(CC1)CCN1C1=C(C(=C(C(=O)N)S2)N)C2=NC=C1 ASDIESYCZFFZGW-UHFFFAOYSA-N 0.000 description 1
- DJSJDIQLCLCNPH-UHFFFAOYSA-N 3-amino-4-[4-(benzenesulfonyl)piperazin-1-yl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1N(CC1)CCN1S(=O)(=O)C1=CC=CC=C1 DJSJDIQLCLCNPH-UHFFFAOYSA-N 0.000 description 1
- HZVIJJJNYRDOIZ-UHFFFAOYSA-N 3-amino-4-[4-(furan-2-carbonyl)piperazin-1-yl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1N(CC1)CCN1C(=O)C1=CC=CO1 HZVIJJJNYRDOIZ-UHFFFAOYSA-N 0.000 description 1
- IRUSTYQLQXOOJY-UHFFFAOYSA-N 3-amino-4-[4-[2-oxo-2-(propan-2-ylamino)ethyl]piperazin-1-yl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1CN(CC(=O)NC(C)C)CCN1C1=CC=NC2=C1C(N)=C(C(N)=O)S2 IRUSTYQLQXOOJY-UHFFFAOYSA-N 0.000 description 1
- JGZXBRYOKKQZLH-UHFFFAOYSA-N 3-amino-4-[butyl(methyl)amino]thieno[2,3-b]pyridine-2-carboxamide Chemical compound CCCCN(C)C1=CC=NC2=C1C(N)=C(C(N)=O)S2 JGZXBRYOKKQZLH-UHFFFAOYSA-N 0.000 description 1
- ACWNTFDPWFESDH-UHFFFAOYSA-N 3-amino-4-[ethyl(methyl)amino]thieno[2,3-b]pyridine-2-carboxamide Chemical compound CCN(C)C1=CC=NC2=C1C(N)=C(C(N)=O)S2 ACWNTFDPWFESDH-UHFFFAOYSA-N 0.000 description 1
- CXVSCRYNGJJGCZ-UHFFFAOYSA-N 3-amino-4-[hydroxy(phenyl)methyl]-6-methylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(N)=O)SC2=NC(C)=CC=1C(O)C1=CC=CC=C1 CXVSCRYNGJJGCZ-UHFFFAOYSA-N 0.000 description 1
- TWIXMQVLRVCHLG-UHFFFAOYSA-N 3-amino-4-[methyl(2-phenylethyl)amino]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=NC=2SC(C(N)=O)=C(N)C=2C=1N(C)CCC1=CC=CC=C1 TWIXMQVLRVCHLG-UHFFFAOYSA-N 0.000 description 1
- TWLXKQYHOKJJSE-UHFFFAOYSA-N 3-amino-4-[methyl(2-pyridin-2-ylethyl)amino]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C=NC=2SC(C(N)=O)=C(N)C=2C=1N(C)CCC1=CC=CC=N1 TWLXKQYHOKJJSE-UHFFFAOYSA-N 0.000 description 1
- VVHYFWFAQKGIRZ-UHFFFAOYSA-N 3-amino-4-[methyl(propyl)amino]thieno[2,3-b]pyridine-2-carboxamide Chemical compound CCCN(C)C1=CC=NC2=C1C(N)=C(C(N)=O)S2 VVHYFWFAQKGIRZ-UHFFFAOYSA-N 0.000 description 1
- WZUJMBPFVFURFH-UHFFFAOYSA-N 3-amino-4-anilinothieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1NC1=CC=CC=C1 WZUJMBPFVFURFH-UHFFFAOYSA-N 0.000 description 1
- VNVATLHJMLMMAG-UHFFFAOYSA-N 3-amino-4-ethoxythieno[2,3-b]pyridine-2-carboxamide Chemical compound CCOC1=CC=NC2=C1C(N)=C(C(N)=O)S2 VNVATLHJMLMMAG-UHFFFAOYSA-N 0.000 description 1
- HRXIMCMKEKORJE-UHFFFAOYSA-N 3-amino-4-formyl-6-methylthieno[2,3-b]pyridine-2-carboxylic acid Chemical compound CC1=CC(C=O)=C2C(N)=C(C(O)=O)SC2=N1 HRXIMCMKEKORJE-UHFFFAOYSA-N 0.000 description 1
- MBAHGHSNYQXCQX-UHFFFAOYSA-N 3-amino-4-methoxythieno[2,3-b]pyridine-2-carboxamide Chemical compound COC1=CC=NC2=C1C(N)=C(C(N)=O)S2 MBAHGHSNYQXCQX-UHFFFAOYSA-N 0.000 description 1
- AXXNTFJEXBNCPU-UHFFFAOYSA-N 3-amino-4-methyl-6-(2-methylpropyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound CC(C)CC1=CC(C)=C2C(N)=C(C(N)=O)SC2=N1 AXXNTFJEXBNCPU-UHFFFAOYSA-N 0.000 description 1
- FVKUOJZYVICQNN-UHFFFAOYSA-N 3-amino-4-methyl-6-morpholin-4-ylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C)=CC=1N1CCOCC1 FVKUOJZYVICQNN-UHFFFAOYSA-N 0.000 description 1
- XFOCPDNNQGEGBM-UHFFFAOYSA-N 3-amino-4-methyl-6-oxo-7h-thieno[2,3-b]pyridine-2-carboxamide Chemical compound CC1=CC(=O)NC2=C1C(N)=C(C(N)=O)S2 XFOCPDNNQGEGBM-UHFFFAOYSA-N 0.000 description 1
- GBWHBAYNQIUYNZ-UHFFFAOYSA-N 3-amino-4-methyl-6-pentylthieno[2,3-b]pyridine-2-carboxamide Chemical compound CCCCCC1=CC(C)=C2C(N)=C(C(N)=O)SC2=N1 GBWHBAYNQIUYNZ-UHFFFAOYSA-N 0.000 description 1
- VBSBZPMZQGFMRI-UHFFFAOYSA-N 3-amino-4-methyl-6-phenylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C)=CC=1C1=CC=CC=C1 VBSBZPMZQGFMRI-UHFFFAOYSA-N 0.000 description 1
- DDLJAULLOOCAIF-UHFFFAOYSA-N 3-amino-4-methyl-6-piperazin-1-ylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C)=CC=1N1CCNCC1 DDLJAULLOOCAIF-UHFFFAOYSA-N 0.000 description 1
- KVDYSDFTDXNFFV-UHFFFAOYSA-N 3-amino-4-methyl-6-piperidin-1-ylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C)=CC=1N1CCCCC1 KVDYSDFTDXNFFV-UHFFFAOYSA-N 0.000 description 1
- YWTKBAVYXMPVCQ-UHFFFAOYSA-N 3-amino-4-morpholin-4-ylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1N1CCOCC1 YWTKBAVYXMPVCQ-UHFFFAOYSA-N 0.000 description 1
- GKSXAWULYJKKFG-UHFFFAOYSA-N 3-amino-4-oxo-7h-thieno[2,3-b]pyridine-2-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1C=CC(=O)C2=C1SC(C(=O)N)=C2N GKSXAWULYJKKFG-UHFFFAOYSA-N 0.000 description 1
- ILQSFQQEUDEIFV-UHFFFAOYSA-N 3-amino-4-phenylmethoxythieno[2,3-b]pyridine-2-carboxylic acid Chemical compound C=12C(N)=C(C(O)=O)SC2=NC=CC=1OCC1=CC=CC=C1 ILQSFQQEUDEIFV-UHFFFAOYSA-N 0.000 description 1
- SEOCAGUJFRUZHY-UHFFFAOYSA-N 3-amino-4-piperazin-1-ylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1N1CCNCC1 SEOCAGUJFRUZHY-UHFFFAOYSA-N 0.000 description 1
- YRZKCGCJNBZWMF-UHFFFAOYSA-N 3-amino-4-piperidin-1-ylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1N1CCCCC1 YRZKCGCJNBZWMF-UHFFFAOYSA-N 0.000 description 1
- YWLMDGSTQYAULA-UHFFFAOYSA-N 3-amino-4-propan-2-yloxythieno[2,3-b]pyridine-2-carboxamide Chemical compound CC(C)OC1=CC=NC2=C1C(N)=C(C(N)=O)S2 YWLMDGSTQYAULA-UHFFFAOYSA-N 0.000 description 1
- YOIPWLKDPWCVGW-UHFFFAOYSA-N 3-amino-4-propan-2-yloxythieno[2,3-b]pyridine-2-carboxylic acid Chemical compound CC(C)OC1=CC=NC2=C1C(N)=C(C(O)=O)S2 YOIPWLKDPWCVGW-UHFFFAOYSA-N 0.000 description 1
- MSSKTGVILPPEGS-UHFFFAOYSA-N 3-amino-4-pyrrolidin-1-ylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1N1CCCC1 MSSKTGVILPPEGS-UHFFFAOYSA-N 0.000 description 1
- SOWGLKSTUAVEQO-UHFFFAOYSA-N 3-amino-6-(1,1-dioxo-1,4-thiazinan-4-yl)-4-ethoxythieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(OCC)=CC=1N1CCS(=O)(=O)CC1 SOWGLKSTUAVEQO-UHFFFAOYSA-N 0.000 description 1
- DYCNTFOXYSCURR-UHFFFAOYSA-N 3-amino-6-(1,4-diazepan-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCCNCC1 DYCNTFOXYSCURR-UHFFFAOYSA-N 0.000 description 1
- HIZOUFBGDXRHIN-UHFFFAOYSA-N 3-amino-6-(2-hydroxyethylamino)-4-methylthieno[2,3-b]pyridine-2-carboxylic acid Chemical compound CC1=CC(NCCO)=NC2=C1C(N)=C(C(O)=O)S2 HIZOUFBGDXRHIN-UHFFFAOYSA-N 0.000 description 1
- RUCYWRWDLUWJCO-UHFFFAOYSA-N 3-amino-6-(3-aminopropylamino)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound CCCC1=CC(NCCCN)=NC2=C1C(N)=C(C(N)=O)S2 RUCYWRWDLUWJCO-UHFFFAOYSA-N 0.000 description 1
- HCRUBOXDRAFRCA-UHFFFAOYSA-N 3-amino-6-(3-carbamoylpiperazin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCNC(C(N)=O)C1 HCRUBOXDRAFRCA-UHFFFAOYSA-N 0.000 description 1
- OBEKFOJHIXGGPJ-UHFFFAOYSA-N 3-amino-6-(3-carbamoylpiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCCC(C(N)=O)C1 OBEKFOJHIXGGPJ-UHFFFAOYSA-N 0.000 description 1
- AQTGJJPOCBCGFT-UHFFFAOYSA-N 3-amino-6-(3-hydroxypiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCCC(O)C1 AQTGJJPOCBCGFT-UHFFFAOYSA-N 0.000 description 1
- APWRCJVCBBEEIP-UHFFFAOYSA-N 3-amino-6-(4-amino-3,3-dimethylpiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(N)C(C)(C)C1 APWRCJVCBBEEIP-UHFFFAOYSA-N 0.000 description 1
- KOKXZQYVAGAQOT-UHFFFAOYSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-(2-phenylethyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1CC(N)CCN1C1=CC(CCC=2C=CC=CC=2)=C(C(N)=C(S2)C(N)=O)C2=N1 KOKXZQYVAGAQOT-UHFFFAOYSA-N 0.000 description 1
- JWBSGYATCDFAJI-UHFFFAOYSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-(3-nitrophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1CC(N)CCN1C1=CC(C=2C=C(C=CC=2)[N+]([O-])=O)=C(C(N)=C(S2)C(N)=O)C2=N1 JWBSGYATCDFAJI-UHFFFAOYSA-N 0.000 description 1
- APNFPTQIHDXSGK-UHFFFAOYSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-(4-fluorophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C1CC(N)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(C(N)=C(S2)C(N)=O)C2=N1 APNFPTQIHDXSGK-UHFFFAOYSA-N 0.000 description 1
- QARXFXDMGDZCEI-AATRIKPKSA-N 3-amino-6-(4-aminopiperidin-1-yl)-4-[(e)-2-(3-methylphenyl)ethenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound CC1=CC=CC(\C=C\C=2C=3C(N)=C(C(N)=O)SC=3N=C(C=2)N2CCC(N)CC2)=C1 QARXFXDMGDZCEI-AATRIKPKSA-N 0.000 description 1
- HPKPLYYIBHMYBD-UHFFFAOYSA-N 3-amino-6-(4-carbamoylpiperazin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCN(C(N)=O)CC1 HPKPLYYIBHMYBD-UHFFFAOYSA-N 0.000 description 1
- MCCFRAKLOFHVJQ-UHFFFAOYSA-N 3-amino-6-(4-carbamoylpiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(C(N)=O)CC1 MCCFRAKLOFHVJQ-UHFFFAOYSA-N 0.000 description 1
- UPWSFSOQWHIWDV-UHFFFAOYSA-N 3-amino-6-(4-ethanimidoylpiperazin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCN(C(C)=N)CC1 UPWSFSOQWHIWDV-UHFFFAOYSA-N 0.000 description 1
- MOQWCSVNHMZWPM-UHFFFAOYSA-N 3-amino-6-(4-hydroxy-4-methylpiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(C)(O)CC1 MOQWCSVNHMZWPM-UHFFFAOYSA-N 0.000 description 1
- JBYCUWHPFNBXOH-UHFFFAOYSA-N 3-amino-6-(4-hydroxypiperidin-1-yl)-4-(trifluoromethyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=1C(C(F)(F)F)=C2C(N)=C(C(=O)N)SC2=NC=1N1CCC(O)CC1 JBYCUWHPFNBXOH-UHFFFAOYSA-N 0.000 description 1
- QMWFVGPXNLPRLN-UHFFFAOYSA-N 3-amino-6-(4-hydroxypiperidin-1-yl)-4-propan-2-yloxythieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(OC(C)C)=CC=1N1CCC(O)CC1 QMWFVGPXNLPRLN-UHFFFAOYSA-N 0.000 description 1
- FTSQTLCAVRPYJK-UHFFFAOYSA-N 3-amino-6-(4-hydroxypiperidin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(O)CC1 FTSQTLCAVRPYJK-UHFFFAOYSA-N 0.000 description 1
- MPMWURQBDNQMRN-UHFFFAOYSA-N 3-amino-6-(4-methylsulfonylpiperazin-1-yl)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCN(S(C)(=O)=O)CC1 MPMWURQBDNQMRN-UHFFFAOYSA-N 0.000 description 1
- GFHSPBYLBDGFBR-UHFFFAOYSA-N 3-amino-6-(dimethylamino)-4-methylthieno[2,3-b]pyridine-2-carboxamide Chemical compound CN(C)C1=CC(C)=C2C(N)=C(C(N)=O)SC2=N1 GFHSPBYLBDGFBR-UHFFFAOYSA-N 0.000 description 1
- PFPRTANUJOTYMF-UHFFFAOYSA-N 3-amino-6-(piperidin-4-ylamino)-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1NC1CCNCC1 PFPRTANUJOTYMF-UHFFFAOYSA-N 0.000 description 1
- KNSMRZPVXRHMIQ-UHFFFAOYSA-N 3-amino-6-[(1-methylpyrrolidin-2-yl)methoxy]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1OCC1CCCN1C KNSMRZPVXRHMIQ-UHFFFAOYSA-N 0.000 description 1
- XCGDPQMNOJJMPS-UHFFFAOYSA-N 3-amino-6-[2-(hydroxymethyl)piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCCCC1CO XCGDPQMNOJJMPS-UHFFFAOYSA-N 0.000 description 1
- DUTHKOSDVJKWEI-UHFFFAOYSA-N 3-amino-6-[3-(aminomethyl)piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCCC(CN)C1 DUTHKOSDVJKWEI-UHFFFAOYSA-N 0.000 description 1
- UENRTQJWFHUCJQ-UHFFFAOYSA-N 3-amino-6-[4-(2,3-dihydroxypropylamino)piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(NCC(O)CO)CC1 UENRTQJWFHUCJQ-UHFFFAOYSA-N 0.000 description 1
- QFRUAVMNUVNWTI-UHFFFAOYSA-N 3-amino-6-[4-(2,4-diaminobutanoyl)piperazin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCN(C(=O)C(N)CCN)CC1 QFRUAVMNUVNWTI-UHFFFAOYSA-N 0.000 description 1
- RVIGRPZMPLJIFN-UHFFFAOYSA-N 3-amino-6-[4-(2,4-diaminobutanoyl)piperazin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxylic acid Chemical compound N=1C=2SC(C(O)=O)=C(N)C=2C(CCC)=CC=1N1CCN(C(=O)C(N)CCN)CC1 RVIGRPZMPLJIFN-UHFFFAOYSA-N 0.000 description 1
- ZULRKOUWUKTCRF-UHFFFAOYSA-N 3-amino-6-[4-(2-aminoacetyl)piperazin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCN(C(=O)CN)CC1 ZULRKOUWUKTCRF-UHFFFAOYSA-N 0.000 description 1
- UUEOHLILXXQVLJ-UHFFFAOYSA-N 3-amino-6-[4-(aminomethyl)piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(CN)CC1 UUEOHLILXXQVLJ-UHFFFAOYSA-N 0.000 description 1
- MVYJRDYFLFBXJB-UHFFFAOYSA-N 3-amino-6-[4-(hydrazinecarbonyl)piperazin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCN(C(=O)NN)CC1 MVYJRDYFLFBXJB-UHFFFAOYSA-N 0.000 description 1
- QABVURJHSPHXDK-UHFFFAOYSA-N 3-amino-6-[4-[(2-hydroxy-3-phenoxypropyl)amino]piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N(CC1)CCC1NCC(O)COC1=CC=CC=C1 QABVURJHSPHXDK-UHFFFAOYSA-N 0.000 description 1
- OCWFYPNVTXVDSR-UHFFFAOYSA-N 3-amino-6-[4-[(2-hydroxy-3-phenylpropyl)amino]piperidin-1-yl]-4-propylthieno[2,3-b]pyridine-2-carboxamide Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N(CC1)CCC1NCC(O)CC1=CC=CC=C1 OCWFYPNVTXVDSR-UHFFFAOYSA-N 0.000 description 1
- CWXOISKTBFIZLC-UHFFFAOYSA-N 3-amino-6-[4-[tert-butyl(dimethyl)silyl]oxypiperidin-1-yl]-2-carbamoylthieno[2,3-b]pyridine-4-carboxylic acid Chemical compound C1CC(O[Si](C)(C)C(C)(C)C)CCN1C1=CC(C(O)=O)=C(C(N)=C(S2)C(N)=O)C2=N1 CWXOISKTBFIZLC-UHFFFAOYSA-N 0.000 description 1
- ORPGMLTYTNMSRW-UHFFFAOYSA-N 3-amino-6-[4-[tert-butyl(dimethyl)silyl]oxypiperidin-1-yl]thieno[2,3-b]pyridine-2,4-dicarboxylic acid Chemical compound C1CC(O[Si](C)(C)C(C)(C)C)CCN1C1=CC(C(O)=O)=C(C(N)=C(S2)C(O)=O)C2=N1 ORPGMLTYTNMSRW-UHFFFAOYSA-N 0.000 description 1
- FKVHDDBDPMFRHH-UHFFFAOYSA-N 3-amino-6-methyl-4-(1-methylpyrrol-2-yl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(N)=O)SC2=NC(C)=CC=1C1=CC=CN1C FKVHDDBDPMFRHH-UHFFFAOYSA-N 0.000 description 1
- ONJBPNNGGRNSAX-UHFFFAOYSA-N 3-amino-6-methyl-4-(4-methylsulfonylphenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(N)=O)SC2=NC(C)=CC=1C1=CC=C(S(C)(=O)=O)C=C1 ONJBPNNGGRNSAX-UHFFFAOYSA-N 0.000 description 1
- KNEOXTRPQLBGQI-UHFFFAOYSA-N 3-amino-6-methyl-4-(4-nitrophenyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(N)=O)SC2=NC(C)=CC=1C1=CC=C([N+]([O-])=O)C=C1 KNEOXTRPQLBGQI-UHFFFAOYSA-N 0.000 description 1
- YCWRGGYWSSTDRJ-UHFFFAOYSA-N 3-amino-6-methyl-4-(morpholine-4-carbonyl)thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(N)=O)SC2=NC(C)=CC=1C(=O)N1CCOCC1 YCWRGGYWSSTDRJ-UHFFFAOYSA-N 0.000 description 1
- BBBCQIXGYZXPMF-BQYQJAHWSA-N 3-amino-6-methyl-4-[(e)-2-phenylethenyl]thieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(N)=O)SC2=NC(C)=CC=1\C=C\C1=CC=CC=C1 BBBCQIXGYZXPMF-BQYQJAHWSA-N 0.000 description 1
- NOKSYMDCYFUTFU-UHFFFAOYSA-N 3-amino-6-methyl-4-piperidin-1-ylthieno[2,3-b]pyridine-2-carboxamide Chemical class C=12C(N)=C(C(N)=O)SC2=NC(C)=CC=1N1CCCCC1 NOKSYMDCYFUTFU-UHFFFAOYSA-N 0.000 description 1
- JBSSTYGLOGKTOZ-UHFFFAOYSA-N 3-amino-6-methyl-4-pyridin-4-ylthieno[2,3-b]pyridine-2-carboxamide Chemical compound C=12C(N)=C(C(N)=O)SC2=NC(C)=CC=1C1=CC=NC=C1 JBSSTYGLOGKTOZ-UHFFFAOYSA-N 0.000 description 1
- JBPLVWLHOPMFOI-UHFFFAOYSA-N 3-amino-6-piperidin-4-yl-4-propyl-3a,7a-dihydrothieno[2,3-b]pyridine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.N=1C2SC(C(N)=O)=C(N)C2C(CCC)=CC=1C1CCNCC1 JBPLVWLHOPMFOI-UHFFFAOYSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CZRHEROEPICLRO-UHFFFAOYSA-N 4,6-dimethyl-2-sulfanylidene-1h-pyridine-3-carbonitrile Chemical compound CC1=CC(C)=C(C#N)C(=S)N1 CZRHEROEPICLRO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SUFAJVWQACWIMG-UHFFFAOYSA-N 4-(3-oxohexanoyl)piperidine-1-carboxylic acid Chemical compound CCCC(=O)CC(=O)C1CCN(C(O)=O)CC1 SUFAJVWQACWIMG-UHFFFAOYSA-N 0.000 description 1
- ZDHKVKPZQKYREU-UHFFFAOYSA-N 4-(chloromethyl)pyridine;hydron;chloride Chemical compound Cl.ClCC1=CC=NC=C1 ZDHKVKPZQKYREU-UHFFFAOYSA-N 0.000 description 1
- BNNGMHGECRORMB-UHFFFAOYSA-N 4-[(4-methoxyphenyl)methoxy]-3-oxobutanoic acid Chemical compound COC1=CC=C(COCC(=O)CC(O)=O)C=C1 BNNGMHGECRORMB-UHFFFAOYSA-N 0.000 description 1
- GGPZNADFJGVDOY-UHFFFAOYSA-N 4-[2-hydroxy-3-(piperidin-4-ylamino)propoxy]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1OCC(O)CNC1CCNCC1 GGPZNADFJGVDOY-UHFFFAOYSA-N 0.000 description 1
- AZTBMGGNYGEVFW-UHFFFAOYSA-N 4-[3-[tert-butyl(dimethyl)silyl]oxypropyl]-6-oxo-2-sulfanyl-1H-pyridine-3-carbonitrile morpholine Chemical compound C1COCCN1.CC(C)(C)[Si](C)(C)OCCCC1=CC(=O)NC(S)=C1C#N AZTBMGGNYGEVFW-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- VFHHLXWICXSCSY-UHFFFAOYSA-N 4-carbonochloridoylpiperidine-1-carboxylic acid Chemical class OC(=O)N1CCC(C(Cl)=O)CC1 VFHHLXWICXSCSY-UHFFFAOYSA-N 0.000 description 1
- WIBHKRKASPBZCC-UHFFFAOYSA-N 4-methyl-3-sulfanyl-1h-pyridin-2-one Chemical compound CC=1C=CNC(=O)C=1S WIBHKRKASPBZCC-UHFFFAOYSA-N 0.000 description 1
- SKLMGMMZOKNSLK-UHFFFAOYSA-N 4-methyl-6-(2-methylpropyl)-2-sulfanylidene-1h-pyridine-3-carbonitrile Chemical compound CC(C)CC1=CC(C)=C(C#N)C(S)=N1 SKLMGMMZOKNSLK-UHFFFAOYSA-N 0.000 description 1
- QPHIJOUIZZCDKN-UHFFFAOYSA-N 4-methyl-6-pentyl-2-sulfanylidene-1h-pyridine-3-carbonitrile Chemical compound CCCCCC1=CC(C)=C(C#N)C(S)=N1 QPHIJOUIZZCDKN-UHFFFAOYSA-N 0.000 description 1
- MNGVMTLVKIDUTA-UHFFFAOYSA-N 4-methylpyridine;trifluoromethanesulfonic acid Chemical compound CC1=CC=NC=C1.OS(=O)(=O)C(F)(F)F MNGVMTLVKIDUTA-UHFFFAOYSA-N 0.000 description 1
- VISHERBQTUKZQB-UHFFFAOYSA-N 4-methylsulfanyl-1h-pyridin-2-one Chemical compound CSC=1C=CNC(=O)C=1 VISHERBQTUKZQB-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- IGMOYJSFRIASIE-UHFFFAOYSA-N 6-Methylheptan-2,4-dione Chemical compound CC(C)CC(=O)CC(C)=O IGMOYJSFRIASIE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000006418 Brown reaction Methods 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N CH2-hydantoin Natural products O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 101001043764 Homo sapiens Inhibitor of nuclear factor kappa-B kinase subunit alpha Proteins 0.000 description 1
- 101001043754 Homo sapiens Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 108010021699 I-kappa B Proteins Proteins 0.000 description 1
- 102000008379 I-kappa B Proteins Human genes 0.000 description 1
- 230000004950 I-kappaB phosphorylation Effects 0.000 description 1
- 101150101011 IKKbeta gene Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- ZAHXYMFVNNUHCP-UHFFFAOYSA-N Naphazoline nitrate Chemical group O[N+]([O-])=O.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 ZAHXYMFVNNUHCP-UHFFFAOYSA-N 0.000 description 1
- 101100109871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-8 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- MNDDWFONKDZUOW-UHFFFAOYSA-N [1-(3-amino-2-carbamoyl-4-propylthieno[2,3-b]pyridin-6-yl)piperidin-4-yl]carbamic acid Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(CCC)=CC=1N1CCC(NC(O)=O)CC1 MNDDWFONKDZUOW-UHFFFAOYSA-N 0.000 description 1
- BWCBSANEZQMQAI-UHFFFAOYSA-N [6-(2-amino-2-oxoethyl)sulfanyl-5-cyano-4-[(4-methoxyphenyl)methoxymethyl]pyridin-2-yl] trifluoromethanesulfonate Chemical compound C1=CC(OC)=CC=C1COCC1=CC(OS(=O)(=O)C(F)(F)F)=NC(SCC(N)=O)=C1C#N BWCBSANEZQMQAI-UHFFFAOYSA-N 0.000 description 1
- LKWNOCPAGOWGOW-UHFFFAOYSA-N [6-(3-amino-3-oxopropyl)-5-cyano-4-propylpyridin-2-yl] trifluoromethanesulfonate Chemical compound CCCC1=CC(OS(=O)(=O)C(F)(F)F)=NC(CCC(N)=O)=C1C#N LKWNOCPAGOWGOW-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001295 alanines Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 150000008378 aryl ethers Chemical class 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000000998 batch distillation Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- BHFGSISMJQNBIJ-UHFFFAOYSA-N benzyl 4-(3-amino-2-carbamoylthieno[2,3-b]pyridin-4-yl)piperazine-1-carboxylate Chemical compound C=12C(N)=C(C(=O)N)SC2=NC=CC=1N(CC1)CCN1C(=O)OCC1=CC=CC=C1 BHFGSISMJQNBIJ-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- CTOUWUYDDUSBQE-UHFFFAOYSA-N benzyl piperazine-1-carboxylate Chemical compound C1CNCCN1C(=O)OCC1=CC=CC=C1 CTOUWUYDDUSBQE-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical class C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 1
- 235000019820 disodium diphosphate Nutrition 0.000 description 1
- GYQBBRRVRKFJRG-UHFFFAOYSA-L disodium pyrophosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 1
- 229940038485 disodium pyrophosphate Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- OYQVQWIASIXXRT-UHFFFAOYSA-N ethyl 2,4-dioxopentanoate Chemical compound CCOC(=O)C(=O)CC(C)=O OYQVQWIASIXXRT-UHFFFAOYSA-N 0.000 description 1
- XUXBHWPRQGVLRY-UHFFFAOYSA-N ethyl 2-chloro-3-cyano-6-methylpyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC(C)=NC(Cl)=C1C#N XUXBHWPRQGVLRY-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000002474 gonadorelin antagonist Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000028974 hepatocyte apoptotic process Effects 0.000 description 1
- DEBVVCQFYJWTDA-UHFFFAOYSA-N hexadecylalumanylformic acid Chemical compound C([AlH]CCCCCCCCCCCCCCCC)(=O)O DEBVVCQFYJWTDA-UHFFFAOYSA-N 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 102000053365 human CHUK Human genes 0.000 description 1
- 102000053341 human IKBKB Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- MJIVRKPEXXHNJT-UHFFFAOYSA-N lutidinic acid Chemical compound OC(=O)C1=CC=NC(C(O)=O)=C1 MJIVRKPEXXHNJT-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- SCEZYJKGDJPHQO-UHFFFAOYSA-M magnesium;methanidylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C1=CC=CC=C1 SCEZYJKGDJPHQO-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- UYSMZRRJAZHMOJ-UHFFFAOYSA-N methyl 2-(3-amino-2-carbamoyl-4-methylthieno[2,3-b]pyridin-6-yl)oxyacetate Chemical compound COC(=O)COC1=CC(C)=C2C(N)=C(C(N)=O)SC2=N1 UYSMZRRJAZHMOJ-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- HFLMYYLFSNEOOT-UHFFFAOYSA-N methyl 4-chloro-3-oxobutanoate Chemical compound COC(=O)CC(=O)CCl HFLMYYLFSNEOOT-UHFFFAOYSA-N 0.000 description 1
- UJQCANQILFWSDJ-UHFFFAOYSA-N methyl but-2-ynoate Chemical compound COC(=O)C#CC UJQCANQILFWSDJ-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 230000023578 negative regulation of cell adhesion Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- SHNUBALDGXWUJI-UHFFFAOYSA-N pyridin-2-ylmethanol Chemical compound OCC1=CC=CC=N1 SHNUBALDGXWUJI-UHFFFAOYSA-N 0.000 description 1
- PTMBWNZJOQBTBK-UHFFFAOYSA-N pyridin-4-ylmethanol Chemical compound OCC1=CC=NC=C1 PTMBWNZJOQBTBK-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- WBQTXTBONIWRGK-UHFFFAOYSA-N sodium;propan-2-olate Chemical compound [Na+].CC(C)[O-] WBQTXTBONIWRGK-UHFFFAOYSA-N 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- LGLNOWYWBRWLJQ-UHFFFAOYSA-N tert-butyl 4-[[3-(4-carbamoylphenoxy)-2-hydroxypropyl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NCC(O)COC1=CC=C(C(N)=O)C=C1 LGLNOWYWBRWLJQ-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- RNPMBJJXGRQWNI-UHFFFAOYSA-N tert-butyl 4-ethanimidoylpiperazine-1-carboxylate;hydrobromide Chemical compound Br.CC(=N)N1CCN(C(=O)OC(C)(C)C)CC1 RNPMBJJXGRQWNI-UHFFFAOYSA-N 0.000 description 1
- MMPWHAJQEZIIEH-UHFFFAOYSA-N tert-butyl 7-oxa-4-azabicyclo[4.1.0]heptane-4-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC2OC21 MMPWHAJQEZIIEH-UHFFFAOYSA-N 0.000 description 1
- ZGURZEZTENWKRF-UHFFFAOYSA-N tert-butyl N-amino-N-[4-(3-amino-2-carbamoyl-4-propylthieno[2,3-b]pyridin-6-yl)piperazine-1-carbonyl]carbamate Chemical compound CCCc1cc(nc2sc(C(N)=O)c(N)c12)N1CCN(CC1)C(=O)N(N)C(=O)OC(C)(C)C ZGURZEZTENWKRF-UHFFFAOYSA-N 0.000 description 1
- VSZXXWZJHULTAT-UHFFFAOYSA-N tert-butyl n-amino-n-(piperazine-1-carbonyl)carbamate Chemical compound CC(C)(C)OC(=O)N(N)C(=O)N1CCNCC1 VSZXXWZJHULTAT-UHFFFAOYSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- FZRCJGZEADULEQ-UHFFFAOYSA-N tert-butyl-dimethyl-pent-4-ynoxysilane Chemical compound CC(C)(C)[Si](C)(C)OCCCC#C FZRCJGZEADULEQ-UHFFFAOYSA-N 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- XGCSHAYMNOFFNA-UHFFFAOYSA-N thieno[2,3-b]pyridine-2-carboxylic acid Chemical compound C1=CN=C2SC(C(=O)O)=CC2=C1 XGCSHAYMNOFFNA-UHFFFAOYSA-N 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
- C08G63/695—Polyesters containing atoms other than carbon, hydrogen and oxygen containing silicon
- C08G63/6954—Polyesters containing atoms other than carbon, hydrogen and oxygen containing silicon derived from polxycarboxylic acids and polyhydroxy compounds
- C08G63/6956—Dicarboxylic acids and dihydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/91—Polymers modified by chemical after-treatment
- C08G63/914—Polymers modified by chemical after-treatment derived from polycarboxylic acids and polyhydroxy compounds
- C08G63/916—Dicarboxylic acids and dihydroxy compounds
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38631202P | 2002-06-06 | 2002-06-06 | |
US45786703P | 2003-03-26 | 2003-03-26 | |
PCT/US2003/017343 WO2003103661A1 (en) | 2002-06-06 | 2003-06-03 | SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20041154A2 true HRP20041154A2 (en) | 2005-06-30 |
Family
ID=29739900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20041154A HRP20041154A2 (en) | 2002-06-06 | 2004-12-03 | SUBSTITUTED 3-AMINO-THIENO[2,3-b] PYRIDINE-2-CARBO |
Country Status (27)
Country | Link |
---|---|
US (2) | US6964956B2 (zh) |
EP (2) | EP1513516B1 (zh) |
JP (2) | JP4364120B2 (zh) |
KR (1) | KR20050005548A (zh) |
CN (1) | CN100386329C (zh) |
AR (1) | AR040250A1 (zh) |
AT (1) | ATE415966T1 (zh) |
AU (1) | AU2003237330A1 (zh) |
BR (1) | BR0311605A (zh) |
CA (1) | CA2483890C (zh) |
DE (1) | DE60325051D1 (zh) |
DK (1) | DK1513516T3 (zh) |
EA (1) | EA008706B1 (zh) |
ES (1) | ES2318141T3 (zh) |
HK (1) | HK1080737A1 (zh) |
HR (1) | HRP20041154A2 (zh) |
IL (1) | IL164597A0 (zh) |
ME (2) | ME00355B (zh) |
MX (1) | MXPA04011246A (zh) |
NO (1) | NO20044599L (zh) |
NZ (1) | NZ537394A (zh) |
PE (1) | PE20040539A1 (zh) |
PL (1) | PL373424A1 (zh) |
RS (1) | RS105204A (zh) |
TW (1) | TWI296927B (zh) |
UY (1) | UY27834A1 (zh) |
WO (1) | WO2003103661A1 (zh) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7780785B2 (en) | 2001-10-26 | 2010-08-24 | Applied Materials, Inc. | Gas delivery apparatus for atomic layer deposition |
CA2483890C (en) * | 2002-06-06 | 2012-12-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
GB0214268D0 (en) * | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
JP2006512313A (ja) * | 2002-10-31 | 2006-04-13 | アムジェン インコーポレイテッド | 抗炎症剤 |
WO2005012283A1 (en) * | 2003-07-31 | 2005-02-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzothiophene compounds and uses thereof |
US7291733B2 (en) * | 2003-10-10 | 2007-11-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted tricyclic heterocycles and their uses |
UY28647A1 (es) * | 2003-12-05 | 2005-07-29 | Boehringer Ingelheim Pharma | Compuestos de amida del ácido 3-amino-tieno(2,3-b)piridin-2-carboxílico sustituido y procedimientos para su preparación y sus usos |
EP1764367A1 (en) * | 2004-04-12 | 2007-03-21 | Sankyo Company, Limited | Thienopyridine derivatives |
CA2563990A1 (en) * | 2004-05-04 | 2005-11-10 | Sharada Shenvi Labadie | Thienopyridazines as ikk inhibitors |
RU2006142741A (ru) * | 2004-05-04 | 2008-06-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Тиенопиридины как ингибиторы ikk |
CA2566158A1 (en) * | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
AU2005244450B2 (en) * | 2004-05-19 | 2010-08-19 | Solvay Pharmaceuticals Gmbh | Medicaments containing N-sulfamoyl-N'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions |
US7598259B2 (en) | 2004-06-15 | 2009-10-06 | Schering Corporation | mGluR1 antagonists as therapeutic agents |
JP2007277093A (ja) * | 2004-06-21 | 2007-10-25 | Astellas Pharma Inc | 三環系化合物 |
AR050253A1 (es) | 2004-06-24 | 2006-10-11 | Smithkline Beecham Corp | Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento |
PE20060748A1 (es) | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 |
ATE476434T1 (de) * | 2004-12-09 | 2010-08-15 | Xention Ltd | Thienopyridinderivate als kaliumkanalinhibitoren |
EP1683799A1 (de) * | 2005-01-12 | 2006-07-26 | IBFB Pharma GmbH | 3-Amino-6aryl(bzw.6-heteroaryl)-4-R²-thieno[2,3-b]pyridin-2-carbonsäureamide, diese enthaltende pharmazeutische Zubereitungen und deren Verwendung als Inhibitoren der TNFalpha-Freisetzung |
EP1681292A1 (de) * | 2005-01-12 | 2006-07-19 | IBFB Pharma GmbH | 3-Amino-6-aryl(bzw.6-heteroaryl)-thieno¬2,3-b|pyridin-2-carbonsäureamide, diese enthaltende pharmazeutische Zubereitungen und ihre Verwendung als Inhibitoren der TNFalpha-Freisetzung |
WO2006074919A2 (de) * | 2005-01-12 | 2006-07-20 | Curacyte Discovery Gmbh | 3 -AMINO- 6-ARYL (BZW.6-HETEROARYL) -THIENO [2 , 3-B] PYRIDIN-2-CARBONSÄUREAMIDE, DIESE ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN UND IHRE VERWENDUNG ALS INHIBITOREN DER TNFα-FREISETZUNG |
US7465742B2 (en) * | 2005-02-11 | 2008-12-16 | Huanming Chen | Heterocyclic compounds having anti-HBV activity |
JPWO2006129784A1 (ja) * | 2005-06-03 | 2009-01-08 | 独立行政法人理化学研究所 | インターフェロン−α制御剤 |
CN1884262B (zh) * | 2005-06-24 | 2014-06-25 | 中国人民解放军军事医学科学院毒物药物研究所 | 4-氨基哌啶类化合物及其医药用途 |
US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
CN101247804B (zh) | 2005-06-30 | 2012-09-26 | 史密丝克莱恩比彻姆公司 | 化学化合物 |
PE20070619A1 (es) * | 2005-09-27 | 2007-07-02 | Wyeth Corp | TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA |
TW200801016A (en) * | 2005-10-12 | 2008-01-01 | Sankyo Co | Thienopyridine-2-carboxamide derivatives |
WO2007102679A1 (en) * | 2006-03-06 | 2007-09-13 | Je Il Pharmaceutical Co., Ltd. | Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same |
CA2653654A1 (en) * | 2006-06-06 | 2007-12-21 | Boehringer Ingelheim International Gmbh | Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use |
US20080032409A1 (en) * | 2006-08-07 | 2008-02-07 | California Institute Of Technology | Fluorescent biomolecule labeling reagents |
WO2008020622A1 (fr) * | 2006-08-17 | 2008-02-21 | Kyorin Pharmaceutical Co., Ltd. | NOUVEAU COMPOSÉ DE THIÉNO[2,3-d]PYRIMIDINE |
PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
CN101684123B (zh) * | 2008-09-27 | 2013-12-11 | 四川大学 | 2-甲酰胺基噻吩并吡啶衍生物制备方法及医药用途 |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
US8481547B2 (en) * | 2009-12-18 | 2013-07-09 | Janssen Pharmaceutica Nv | Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1 |
US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
ES2606637T3 (es) * | 2012-02-09 | 2017-03-24 | Merck Patent Gmbh | Derivados de furo [3,2- b]piridina como inhibidores de TBK1 e IKK |
KR101468207B1 (ko) * | 2013-02-14 | 2014-12-01 | 한국화학연구원 | 신규한 싸이에노[3,2-b]피리딜 우레아 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-Ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
CN105829296A (zh) | 2013-12-18 | 2016-08-03 | 巴斯夫欧洲公司 | 带有亚胺衍生的取代基的唑类化合物 |
RU2557550C1 (ru) * | 2014-06-16 | 2015-07-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" | Антидот гербицида 2,4-дихлорфеноксиуксусной кислоты на подсолнечнике |
US10758522B2 (en) | 2015-06-01 | 2020-09-01 | The Scripps Research Institute | Small molecule analogs of the nemo binding peptide |
KR20180073600A (ko) * | 2015-11-03 | 2018-07-02 | 루 라이센스 에이비 | 과증식성 장애의 치료를 위한 화합물 |
TWI753910B (zh) * | 2016-05-16 | 2022-02-01 | 美商拜歐斯瑞克斯公司 | 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途 |
CN112638382A (zh) * | 2018-06-06 | 2021-04-09 | 国家医疗保健研究所 | 作为epac抑制剂的噻吩并[2,3-b]吡啶衍生物及其药物用途 |
US11014906B2 (en) | 2018-08-21 | 2021-05-25 | University Of South Carolina | Quinoline-based compounds and methods of inhibiting CDK8/19 |
WO2020160537A1 (en) | 2019-02-01 | 2020-08-06 | University Of South Carolina | Bicyclic pyridine compositions and methods of using the same for cancer therapy |
US20220226343A1 (en) * | 2019-05-21 | 2022-07-21 | University Of South Carolina | 3-amino-4-[4-[4 (dimethylcarbamoyl) phenyl]-1,4-diazepan-1-yl]thieno[2,3-b]pyridine-2-carboxamide for use in cancer therapy and formulations comprising the same |
CN113248353B (zh) * | 2021-07-01 | 2022-02-25 | 山东国邦药业有限公司 | 一种2,4-二氯-5-氟苯乙酮的制备方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS50140487A (zh) * | 1974-04-15 | 1975-11-11 | ||
WO1992003427A1 (en) | 1990-08-17 | 1992-03-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Ketone compound and remedy for osteoporosis |
US5852046A (en) | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
JP3254843B2 (ja) * | 1993-08-09 | 2002-02-12 | 三菱ウェルファーマ株式会社 | 新規縮合ヘテロ環誘導体 |
US5350748A (en) | 1993-08-18 | 1994-09-27 | Warner-Lambert Company | 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion |
DE4420922A1 (de) | 1994-06-16 | 1995-12-21 | Bayer Ag | Verfahren zur Herstellung von Benzothiophenderivaten |
US5656638A (en) * | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
US6313301B1 (en) * | 1997-08-13 | 2001-11-06 | Takeda Chemical Industries, Ltd. | Thienopyridine derivatives, their intermediates and production thereof |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
ES2219033T3 (es) * | 1998-07-22 | 2004-11-16 | Daiichi Suntory Pharma Co., Ltd. | Inhibidores de nf-kappa b que contienen derivados de indano como ingrediente activo. |
TW564247B (en) | 1999-04-08 | 2003-12-01 | Akzo Nobel Nv | Bicyclic heteraromatic compound |
WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
EP1194425B1 (de) | 1999-06-23 | 2005-08-10 | Aventis Pharma Deutschland GmbH | Substituierte benzimidazole |
DE19951360A1 (de) | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
EP1268477B1 (en) | 2000-03-15 | 2010-04-21 | Sanofi-Aventis Deutschland GmbH | Substituted beta-carbolines with ikb-kinase inhibiting activity |
JP3649395B2 (ja) * | 2000-04-27 | 2005-05-18 | 山之内製薬株式会社 | 縮合ヘテロアリール誘導体 |
TR200402656T4 (tr) * | 2000-06-06 | 2004-11-22 | Pfizer Products Inc. | Antikanser ajanları olarak faydalı tiyofen türevleri |
KR20030064773A (ko) | 2000-10-26 | 2003-08-02 | 툴라릭, 인코포레이티드 | 항염증제 |
CA2453428A1 (en) | 2001-07-20 | 2003-01-30 | Emerald Bioagriculture Corporation | Plant ion channels and methods |
WO2003037886A2 (en) | 2001-10-30 | 2003-05-08 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
CA2483890C (en) | 2002-06-06 | 2012-12-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
US6974870B2 (en) | 2002-06-06 | 2005-12-13 | Boehringer Ingelheim Phamaceuticals, Inc. | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
WO2005001849A1 (fr) | 2003-06-27 | 2005-01-06 | Eremeev, Petr Igorevich | Procede de prise en charge du combustible nucleaire epuise |
WO2005012283A1 (en) | 2003-07-31 | 2005-02-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzothiophene compounds and uses thereof |
US7291733B2 (en) | 2003-10-10 | 2007-11-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted tricyclic heterocycles and their uses |
UY28647A1 (es) | 2003-12-05 | 2005-07-29 | Boehringer Ingelheim Pharma | Compuestos de amida del ácido 3-amino-tieno(2,3-b)piridin-2-carboxílico sustituido y procedimientos para su preparación y sus usos |
JP2005194198A (ja) | 2003-12-26 | 2005-07-21 | Takeda Chem Ind Ltd | チエノピリジン化合物 |
AU2005275182A1 (en) * | 2004-07-22 | 2006-02-23 | Ptc Therapeutics, Inc. | Thienopyridines for treating Hepatitis C |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
EP1805187A1 (en) | 2004-10-21 | 2007-07-11 | Pfizer, Inc. | Inhibitors of hepatitis c virus protease, and compositions and treatments using the same |
US20060293709A1 (en) | 2005-06-24 | 2006-12-28 | Bojarski Raymond A | Tissue repair device |
-
2003
- 2003-06-03 CA CA2483890A patent/CA2483890C/en not_active Expired - Fee Related
- 2003-06-03 KR KR10-2004-7019850A patent/KR20050005548A/ko not_active Application Discontinuation
- 2003-06-03 NZ NZ537394A patent/NZ537394A/en unknown
- 2003-06-03 AT AT03736796T patent/ATE415966T1/de active
- 2003-06-03 UY UY27834A patent/UY27834A1/es not_active Application Discontinuation
- 2003-06-03 JP JP2004510780A patent/JP4364120B2/ja not_active Expired - Fee Related
- 2003-06-03 MX MXPA04011246A patent/MXPA04011246A/es not_active Application Discontinuation
- 2003-06-03 US US10/453,175 patent/US6964956B2/en not_active Expired - Lifetime
- 2003-06-03 PL PL03373424A patent/PL373424A1/xx not_active Application Discontinuation
- 2003-06-03 ES ES03736796T patent/ES2318141T3/es not_active Expired - Lifetime
- 2003-06-03 BR BR0311605-0A patent/BR0311605A/pt not_active Withdrawn
- 2003-06-03 ME MEP-2008-535A patent/ME00355B/me unknown
- 2003-06-03 EP EP03736796A patent/EP1513516B1/en not_active Expired - Lifetime
- 2003-06-03 ME MEP-535/08A patent/MEP53508A/xx unknown
- 2003-06-03 DK DK03736796T patent/DK1513516T3/da active
- 2003-06-03 EA EA200401541A patent/EA008706B1/ru not_active IP Right Cessation
- 2003-06-03 DE DE60325051T patent/DE60325051D1/de not_active Expired - Lifetime
- 2003-06-03 AU AU2003237330A patent/AU2003237330A1/en not_active Abandoned
- 2003-06-03 EP EP08164478A patent/EP2008654A1/en not_active Withdrawn
- 2003-06-03 WO PCT/US2003/017343 patent/WO2003103661A1/en active Application Filing
- 2003-06-03 RS YU105204A patent/RS105204A/sr unknown
- 2003-06-03 CN CNB038099586A patent/CN100386329C/zh not_active Expired - Fee Related
- 2003-06-04 PE PE2003000560A patent/PE20040539A1/es not_active Application Discontinuation
- 2003-06-05 TW TW092115243A patent/TWI296927B/zh active
- 2003-06-06 AR ARP030102022A patent/AR040250A1/es not_active Suspension/Interruption
-
2004
- 2004-10-14 IL IL16459704A patent/IL164597A0/xx unknown
- 2004-10-25 NO NO20044599A patent/NO20044599L/no not_active Application Discontinuation
- 2004-12-03 HR HR20041154A patent/HRP20041154A2/hr not_active Application Discontinuation
-
2005
- 2005-08-18 US US11/206,707 patent/US7405225B2/en not_active Expired - Lifetime
-
2006
- 2006-01-18 HK HK06100816A patent/HK1080737A1/xx not_active IP Right Cessation
-
2009
- 2009-02-18 JP JP2009035787A patent/JP2009102447A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20041154A2 (en) | SUBSTITUTED 3-AMINO-THIENO[2,3-b] PYRIDINE-2-CARBO | |
CN105829307B (zh) | 用作tnf活性调节剂的四氢咪唑并吡啶衍生物 | |
US6974870B2 (en) | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | |
US20060270671A1 (en) | Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | |
US20080008720A1 (en) | Substituted Tricyclic Heterocycles and their Uses | |
US20050187209A1 (en) | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | |
CN111601807B (zh) | Menin-mll相互作用的外型-氮杂螺抑制剂 | |
US7329764B2 (en) | Substitute benzothiophene compounds | |
EP2029608A1 (en) | Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use | |
UA80431C2 (en) | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20080602 Year of fee payment: 6 |
|
OBST | Application withdrawn |